News

Categories
Sign up
Featured Posts
Archive
Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

Alpha Tau Announces the Publication of Exceptional Clinical Data from Alpha DaRT, its Novel Alpha Ra

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors. Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a novel alpha radiation cancer treatment, in the International Journal of Radiation Oncology, Biology, and Physics, the official journal of the American Society for Radiation Oncology. The objectives of the trial, conducted in Israel and in Italy, were to establish the feasibility, safety and efficacy of Alpha DaRT for management of patients with squamous cell carcinoma of the skin and head and neck region. All 28 evaluable treat

Alpha Tau

Looking for clinical trials?

  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon